These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 17503469)
1. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Arnold JT; Liu X; Allen JD; Le H; McFann KK; Blackman MR Prostate; 2007 Aug; 67(11):1152-62. PubMed ID: 17503469 [TBL] [Abstract][Full Text] [Related]
2. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Arnold JT; Le H; McFann KK; Blackman MR Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203 [TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY; Ly LH; Peehl DM; Feldman D Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780 [TBL] [Abstract][Full Text] [Related]
4. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Sadar MD; Gleave ME Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779 [TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465 [TBL] [Abstract][Full Text] [Related]
6. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Le H; Arnold JT; McFann KK; Blackman MR Am J Physiol Endocrinol Metab; 2006 May; 290(5):E952-60. PubMed ID: 16368782 [TBL] [Abstract][Full Text] [Related]
7. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Quéro L; Giocanti N; Hennequin C; Favaudon V Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. He D; Falany CN Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250 [TBL] [Abstract][Full Text] [Related]
9. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Yan J; Xie B; Capodice JL; Katz AE Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S; Agoulnik IU; Weigel NL Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350 [TBL] [Abstract][Full Text] [Related]
11. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. Maggiolini M; Recchia AG; Carpino A; Vivacqua A; Fasanella G; Rago V; Pezzi V; Briand PA; Picard D; Andò S J Mol Endocrinol; 2004 Jun; 32(3):777-91. PubMed ID: 15171712 [TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway. Sun HZ; Yang TW; Zang WJ; Wu SF J Endocrinol; 2010 Mar; 204(3):311-8. PubMed ID: 20007738 [TBL] [Abstract][Full Text] [Related]
13. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
14. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor. Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097 [TBL] [Abstract][Full Text] [Related]
15. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608 [TBL] [Abstract][Full Text] [Related]
16. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Lu S; Wang A; Lu S; Dong Z Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434 [TBL] [Abstract][Full Text] [Related]
18. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725 [TBL] [Abstract][Full Text] [Related]
19. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
20. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Wang LG; Liu XM; Kreis W; Budman DR Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]